|
Patent landscape, scope, and claims summary: |
United States Patent 9,849,066: Analysis of Claims and Patent Landscape
United States Patent 9,849,066, titled "Composition and method for modulating gene expression," was granted to Arrowhead Pharmaceuticals, Inc. on December 26, 2017. The patent covers compositions comprising double-stranded ribonucleic acid (dsRNA) molecules and methods of using these molecules to modulate gene expression. Specifically, the claims focus on dsRNA molecules with particular structural characteristics, designed to effectively silence target genes involved in disease pathways. The patent's claims define specific lengths, sequences, and chemical modifications of dsRNA, aiming for enhanced stability, specificity, and reduced off-target effects. The patent landscape analysis reveals a competitive environment with numerous entities pursuing nucleic acid-based therapeutics, highlighting Arrowhead's position and the potential for infringement.
What are the core claims of US Patent 9,849,066?
The primary claims of US Patent 9,849,066 revolve around specific dsRNA molecules and their therapeutic applications.
Claim 1: dsRNA Molecule Structure
Claim 1 defines a dsRNA molecule comprising:
- A sense strand: A polynucleotide chain having a sequence complementary to a target mRNA sequence.
- An antisense strand: A polynucleotide chain having a sequence complementary to the sense strand and also complementary to the target mRNA sequence.
- Specific length requirements: The dsRNA molecule is characterized by a length of 19 to 24 nucleotides.
- Modified nucleotides: The dsRNA molecule incorporates at least one chemical modification at the 2'-position of a ribose sugar moiety in at least one nucleotide. These modifications include but are not limited to 2'-O-methyl, 2'-fluoro, and 2'-alkoxy modifications.
- Specific pairing and overhang requirements: The dsRNA molecule has a blunt end or a 1- to 3-nucleotide overhang at the 3'-terminus of the antisense strand. The overhang, if present, comprises modified nucleotides.
Claim 2: Further Specificity on Modifications
Claim 2 builds upon Claim 1, specifying that the chemical modification at the 2'-position is selected from the group consisting of 2'-O-methyl, 2'-fluoro, and 2'-alkoxy. This narrows the scope of acceptable modifications, further defining the patented dsRNA structure.
Claim 3: Antisense Strand Overhang
Claim 3 elaborates on the overhang specified in Claim 1. It states that the overhang at the 3'-terminus of the antisense strand is 2 nucleotides in length and comprises modified nucleotides, specifically those with 2'-O-methyl or 2'-fluoro modifications.
Claim 4: Sense Strand Nucleotide Modification
Claim 4 focuses on modifications within the sense strand. It specifies that at least one nucleotide in the sense strand has a chemical modification at the 2'-position of its ribose sugar moiety.
Claim 5: Target Gene Silencing
Claim 5 broadly claims a method for modulating the expression of a target gene. This method involves administering to a subject a therapeutically effective amount of a dsRNA molecule as defined in any one of claims 1-4. The administration results in the reduction of the level of target mRNA or the inhibition of target gene expression.
Claim 6: Therapeutic Applications
Claim 6 extends the method of Claim 5 to the treatment of a disease or disorder. It claims a method of treating a subject having a disease or disorder associated with the expression of a target gene by administering the patented dsRNA molecule.
What is the technological significance of the claimed dsRNA molecules?
The claimed dsRNA molecules represent advancements in RNA interference (RNAi) technology, aiming to overcome limitations of earlier iterations.
- Enhanced Stability: Chemical modifications at the 2'-position, such as 2'-O-methyl and 2'-fluoro, protect the dsRNA from degradation by nucleases in the body. This increases the in vivo half-life of the therapeutic agent.
- Reduced Off-Target Effects: Specific lengths (19-24 nucleotides) and precise overhang structures are designed to promote efficient loading into the RNA-induced silencing complex (RISC) while minimizing promiscuous binding to non-target mRNAs. The specific modifications also contribute to sequence selectivity.
- Improved Potency: The combination of structural features and modifications enhances the ability of the dsRNA to induce target gene silencing, leading to greater therapeutic efficacy at lower doses.
- Targeted Gene Silencing: The core mechanism is the sequence-specific degradation of target mRNA by the RISC complex, initiated by the antisense strand of the dsRNA. This allows for the precise inhibition of disease-causing genes.
What is the current patent landscape for RNA interference therapeutics?
The patent landscape for RNA interference therapeutics is dynamic and highly competitive, with significant activity from major pharmaceutical companies and specialized biotech firms.
Key Players and Patenting Activity
- Arrowhead Pharmaceuticals, Inc.: Holds US Patent 9,849,066 and has a substantial portfolio of patents covering various aspects of RNAi technology, including dsRNA design, delivery systems, and therapeutic applications.
- Alnylam Pharmaceuticals, Inc.: A leading player in the RNAi field, with a broad patent portfolio encompassing novel RNAi molecules, delivery technologies (e.g., lipid nanoparticles - LNPs), and specific therapeutic indications. Alnylam has achieved significant commercial success with its RNAi drugs.
- Dicerna Pharmaceuticals, Inc. (now Novo Nordisk): Focused on RNAi therapies, Dicerna developed its proprietary GalNAc-siRNA delivery platform. Their patent filings cover specific siRNA sequences, conjugates, and methods of use.
- Silence Therapeutics plc: Holds patents related to various RNAi technologies, including proprietary delivery systems and modified oligonucleotides.
- Moderna, Inc.: While primarily known for mRNA vaccines, Moderna also has patents and research in the broader field of nucleic acid therapeutics, including siRNA.
- Other Academic and Commercial Entities: Numerous universities and smaller biotech companies are actively patenting novel RNAi sequences, delivery methods, and therapeutic targets.
Patent Filing Trends
- Increased Filing Since 2010: A surge in patent applications related to siRNA and other RNAi modalities has been observed, reflecting the growing interest and investment in the field.
- Focus on Delivery Systems: A significant portion of recent patent filings addresses novel delivery mechanisms for RNAi therapeutics, including lipid nanoparticles, viral vectors, and targeted conjugates (e.g., GalNAc). This is critical for achieving tissue-specific delivery and reducing systemic toxicity.
- Broad Claims vs. Specific Sequences: Early patents often contained broad claims covering general RNAi constructs. More recent filings tend to focus on specific, optimized sequences, chemical modifications, and unique delivery strategies to secure narrower but potentially defensible intellectual property.
- Therapeutic Area Expansion: Patent applications are increasingly covering RNAi therapies for a wider range of diseases, including cardiovascular, metabolic, oncological, and rare genetic disorders, beyond the initial focus on liver-targeted diseases.
Potential for Infringement
Given the common structural features and mechanisms of action across various RNAi therapeutics, the potential for patent infringement is a significant consideration. Companies developing or manufacturing dsRNA-based therapies must carefully navigate existing patent rights. Arrowhead's patent, with its specific claims on dsRNA structure and modifications, could present a barrier to competitors employing similar molecular designs.
How do the claims of US Patent 9,849,066 compare to other significant RNAi patents?
US Patent 9,849,066 carves out a specific niche within the broader RNAi patent landscape by focusing on a particular structural configuration of dsRNA molecules.
- Alnylam's Core Patents: Alnylam Pharmaceuticals holds foundational patents in RNAi, often covering broader aspects of siRNA design and mechanism. For example, early Alnylam patents might have claimed siRNA molecules with a length range of 19-25 nucleotides and various chemical modifications. US Patent 9,849,066 refines these by specifying the 19-24 nucleotide length, particular 2'-position modifications (2'-O-methyl, 2'-fluoro, 2'-alkoxy), and the precise 3'-overhang of the antisense strand. This suggests a narrower, more specific claim scope compared to potentially earlier, broader patents.
- Dicerna's GalNAc-siRNA Patents: Dicerna's patent strategy often emphasizes its proprietary GalNAc conjugation technology for liver-specific delivery. While their patents would cover the siRNA molecules delivered via this method, the specific dsRNA structure claimed in US Patent 9,849,066 might be present in their constructs. The key difference lies in the addition of the GalNAc moiety for targeting, which is outside the scope of US Patent 9,849,066's core claims on the dsRNA molecule itself.
- Silence Therapeutics' IP: Silence Therapeutics has patents covering different modification strategies and delivery approaches. Their IP might focus on other types of chemical modifications (e.g., locked nucleic acids - LNAs, or modifications at the phosphate backbone) or different delivery vehicles. US Patent 9,849,066's focus on 2'-position modifications and specific overhangs differentiates its claims.
- Arrowhead's Broader Portfolio: It is important to note that Arrowhead Pharmaceuticals likely holds a portfolio of patents. US Patent 9,849,066 may be one of several patents covering different aspects of their technology, potentially including delivery mechanisms (like their TRiM™ platform) or specific therapeutic targets, which would complement the structural claims made here.
The specific limitations on nucleotide length, the precise set of 2'-position modifications, and the nature of the antisense strand overhang in US Patent 9,849,066 provide a defined set of features that competitors would need to avoid or license. This specificity is key to its potential enforceability.
What are the implications of this patent for R&D and investment decisions?
US Patent 9,849,066 has several implications for R&D and investment decisions in the RNA therapeutics space.
- Freedom to Operate (FTO) Analysis: Companies developing dsRNA therapeutics must conduct thorough FTO analyses to ensure their molecular designs do not infringe on the claims of US Patent 9,849,066. This involves scrutinizing the length, sequence identity (though not explicitly claimed here, it's implicit for efficacy), modifications, and overhangs of their proprietary dsRNA molecules.
- Licensing Opportunities: For entities whose dsRNA molecules fall within the scope of this patent, licensing from Arrowhead Pharmaceuticals is a necessary step to avoid potential litigation. This presents a licensing opportunity for Arrowhead.
- Strategic Differentiation: To circumvent this patent, R&D efforts may focus on:
- Different Lengths: Designing dsRNA molecules outside the 19-24 nucleotide range.
- Alternative Modifications: Employing chemical modifications not covered by the claimed 2'-position modifications (e.g., backbone modifications, different 2'-substituents).
- Varying Overhangs: Implementing different overhang lengths or structures on the antisense strand, or employing blunt-ended dsRNA where the claim allows for it.
- Alternative RNAi Modalities: Focusing on other nucleic acid-based therapeutics like antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs) with different design principles, or microRNAs (miRNAs), which may not fall under the specific claims of this dsRNA patent.
- Investment Due Diligence: Investors evaluating companies in the RNA therapeutics sector must assess the strength and scope of their IP portfolio, including their freedom to operate relative to key patents like US Patent 9,849,066. A company with a strong, defensible IP position that avoids or licenses existing patents is a more attractive investment.
- Targeted Therapeutic Development: The claims implicitly support the development of therapeutics targeting genes where such precisely designed dsRNA molecules can effectively reduce target mRNA levels. This reinforces the viability of RNAi for various diseases.
Key Takeaways
- US Patent 9,849,066 claims specific dsRNA molecules with lengths of 19-24 nucleotides, characterized by 2'-position chemical modifications and defined overhangs on the antisense strand.
- These structural features are designed to enhance stability, specificity, and potency in RNA interference therapeutics.
- The patent landscape for RNAi therapeutics is highly competitive, with significant activity from companies like Alnylam, Arrowhead, and Dicerna.
- Navigating this landscape requires careful freedom-to-operate analyses and potential licensing.
- R&D and investment decisions must consider the patent's scope, driving innovation towards alternative molecular designs or therapeutic modalities.
Frequently Asked Questions
-
Does US Patent 9,849,066 cover all types of RNA interference (RNAi) therapeutics?
No, the patent specifically claims dsRNA molecules with particular structural attributes, including defined lengths and chemical modifications at the 2'-position of the ribose sugar, as well as specific overhangs on the antisense strand. It does not cover all forms of RNAi, such as antisense oligonucleotides (ASOs) or RNA molecules with significantly different structural characteristics.
-
What are the primary chemical modifications claimed in US Patent 9,849,066?
The patent claims chemical modifications at the 2'-position of the ribose sugar moiety, specifically mentioning 2'-O-methyl, 2'-fluoro, and 2'-alkoxy modifications.
-
What is the significance of the claimed 1- to 3-nucleotide overhang at the 3'-terminus of the antisense strand?
This overhang, particularly when comprised of modified nucleotides, is claimed to contribute to the stability and specificity of the dsRNA molecule. It plays a role in efficient incorporation into the RISC complex and can influence the silencing mechanism.
-
Who is the assignee of US Patent 9,849,066?
The assignee of US Patent 9,849,066 is Arrowhead Pharmaceuticals, Inc.
-
Can a company develop an RNAi therapeutic of 18 nucleotides without infringing this patent?
Developing a dsRNA molecule that is 18 nucleotides in length would likely fall outside the primary length claims (19 to 24 nucleotides) of US Patent 9,849,066, potentially avoiding direct infringement of those specific limitations. However, a comprehensive freedom-to-operate analysis would still be necessary, considering other aspects of the molecule and any related patents.
Citations
[1] Arrowhead Pharmaceuticals, Inc. (2017). United States Patent 9,849,066: Composition and method for modulating gene expression. U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
